| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6061961 | Annals of Allergy, Asthma & Immunology | 2015 | 4 Pages |
Abstract
Infliximab can trigger systemic reactions that hinder its administration. The present desensitization protocol appears to be safe and effective and it can be considered in patients whose inflammatory bowel disease responds well to infliximab but who develop systemic adverse reactions.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Ahmad A. MD, Moheb N. MD, Yesim MD, Sami L. MD, DrPH,